Comparative Pharmacology
Head-to-head clinical analysis: VARDENAFIL HYDROCHLORIDE versus VIAGRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VARDENAFIL HYDROCHLORIDE versus VIAGRA.
VARDENAFIL HYDROCHLORIDE vs VIAGRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). It enhances the effect of nitric oxide (NO) by inhibiting PDE5, which is responsible for degradation of cGMP in the corpus cavernosum. This results in increased cGMP levels, leading to smooth muscle relaxation and increased blood flow to the corpus cavernosum, thereby facilitating penile erection.
Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels in corpus cavernosum, leading to smooth muscle relaxation and blood flow into the penis.
10 mg orally once daily as needed, approximately 60 minutes before sexual activity; maximum dose 20 mg; maximum frequency once daily.
50 mg orally once as needed approximately 1 hour before sexual activity; range 25-100 mg based on efficacy and tolerability. Maximum dosing frequency: once per day.
None Documented
None Documented
Terminal elimination half-life is approximately 4-5 hours in healthy subjects. In elderly patients (≥65 years) or those with hepatic impairment (Child-Pugh A/B), half-life may be prolonged up to 6-8 hours.
Terminal elimination half-life approximately 4 hours (range 3–5 hours). No significant accumulation with recommended dosing.
Primarily hepatic metabolism (CYP3A4, minor CYP2C9) followed by fecal excretion (approximately 91-95% of dose as metabolites) and renal excretion (approximately 2-6% as unchanged drug).
Renal (approximately 80% as metabolites, 20% as unchanged drug in feces), biliary/fecal (about 13% unchanged in feces). Total clearance 41 L/h.
Category A/B
Category C
PDE5 Inhibitor
PDE5 Inhibitor